JPRN-UMIN000024634
Completed
Phase 1
Multi-virus (Cytomegalovirus, EB virus, Adenovirus, BK virus, and HHV-6) specific Cytotoxic T-Lymphocytes from HLA-haploidentical or more HLA-matched relative donor to persistent viral infection after hematopoietic cell transplantation (multi-center, prospective phase I/II study) - Multi-virus specific CTL from HLA-haploidentical or more HLA-matched relative donor to persistent viral infection after HCT.
Medical Hospital, Tokyo Medical and Dental University0 sites3 target enrollmentStarted: November 1, 2016Last updated:
Overview
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 3
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- ot applicable to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)ATG, Campath\-1H or other anti\-T cell monoclonal antibodies within 28 days before the entry. 2\)Severe infectious diseases except for ADV, BKV, CMV, EBV, or HHV6 infection. 3\)Donor lymphocyte infusion within 28 days before the entry 4\)Uncontrollable acute GVHD (grade III\-IV) despite standard immunosuppressive therapy (for example; prednisolone up to 0\.5mg/kg/day) 5\)Relapse of hematological malignancy that is considered as an indication for HSCT 6\)History of malignancy, except for (1\) the patients malignancy that is to be treated with HCT, (2\) malignancy in remission for more than 5 years or (3\) totally resected GI or skin cancer 7\)SpO2 on room air \< 90% 8\)Patients with any of the following pulmonary function tests (PFT) results: i) FEV1/vital capacity \< 70% for 16 years and older, and \< 80% for age between 6 years and 15 years. ii) %VC \<80% iii) FEV1 \<75% of predicted with 10% decline compared before HCT. 9\)Incidence of bronchiolitis obliterans (BO), or bronchiolitis obliterans syndrome (BOS) on high\-resolution computed tomography. 10\)KL\-6 \>500U/mL for patients 16 years and older, and \>250U/mL for patients 15 years and under 11\)Smoking after HSCT 12\)Ejection fraction less than 40% 13\)Patient judged not eligible for this study by the investigator.
Investigators
Similar Trials
Completed
Phase 1
Multi-virus specific T cell therapy for refractory viral infections after hematopoietic stem cell transplantatioJPRN-jRCTa030190229Morio Tomohiro3
Active, not recruiting
Phase 1
virus-specific immunotherapyPatients undergoing allogeneic HSCT undergo weekly screening for HAdV and CMV PCR. In case of viraemia = 100 copies/ml PB preemptive antiviral with either Gancyclovir or Cidofovir conform to the local HSCT-infection-SOPs. In case of increasing viral load despite adequte virostatic treatment for two weeks, the administration of donor derived (or receipient derived in case of donor CMV negativity and receipient positivity before HSCT) virus specific T cells is foreseenMedDRA version: 18.1 Level: LLT Classification code 10050541 Term: Cytomegalovirus antigen positive System Organ Class: 100000004848Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2013-002492-17-ATSt. Anna Kinderkrebsforschung30
Withdrawn
Phase 1
Virus-specific ImmunoTherapy Following Allogeneic Stem Cell TransplantationCytomegalovirus InfectionAdenovirus InfectionNCT02702427St. Anna Kinderkrebsforschung
Unknown
Phase 1
Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic InfectionsPathogen InfectionEBV InfectionCMV InfectionAdenovirus InfectionBKV InfectionFungus InfectionTuberculosisNCT03159364Shenzhen Geno-Immune Medical Institute100
Recruiting
Phase 3
Empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia: a multicenter, open-label randomized controlled clinical trialHIV/AIDSTuberculosisCytomegalovirus pneumoniaRespiratoryPaediatricsPACTR201904797961340Servicio Madrileno de Salud Fundacion para la Investigacion Biomedica Hospital Universitario 12 de Octubre624